Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori

Clicks: 428
ID: 113015
2007
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #3 of 10 articles by views in alimentary pharmacology & therapeutics

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Drug resistance was a strong predictor of efficacy across triple therapies for the eradication of H. pylori in adults. Resistance to either clarithromycin or metronidazole, but not both simultaneously, may be overcome by using quadruple therapies, especially those containing both clarithromycin and …
Reference Key
l2007alimentarymeta-analysis: Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Fischbach L;Evans EL;;
Journal alimentary pharmacology & therapeutics
Year 2007
DOI
DOI not found
URL
https://www.ncbi.nlm.nih.gov/pubmed/17635369
Keywords
meta-analysis National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome adult drug resistance drug therapy combination anti-bacterial agents / therapeutic use* helicobacter infections / drug therapy* helicobacter pylori / drug effects* pmid:17635369 doi:10.1111/j.1365-2036.2007.03386.x l fischbach e l evans bacterial / drug effects*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.